UPDATE: Evercore ISI Starts Inhibrx Inc. (INBX) at Outperform

(updating comment)

Evercore ISI analyst Josh Schimmer initiates coverage on Inhibrx Inc. (NASDAQ: INBX) with a Outperform rating and a price target of $30.00.

The analyst comments "With a unique pipeline that includes what we deem a lower-risk protein replacement play in ‘101 for AATD and an emerging oncology portfolio which has established clinical proof of concept with ‘109, we see INBX as offering multiple ways to win."

For an analyst ratings summary and ratings history on Inhibrx Inc. click here. For more ratings news on Inhibrx Inc. click here.

Shares of Inhibrx Inc. closed at $17.04 yesterday.

You May Also Be Interested In

• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
• Axis Capital Limited Upgrades Colgate-Palmolive India (CLGT:IN) to Add (2)
• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral